Skip to main content
OpenTrials
Completed

NCT Number: NCT02837731

Fluid Responsiveness Evaluation in Sepsis-associated Hypotension

This study assesses the mean difference in fluid balance at ICU discharge and associated patient outcomes, based on a dynamic assessment of fluid responsiveness in septic patients with refractory hypotension in an ICU setting.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Royal Surrey County Hospital, Guildford, United Kingdom

Loading trial locations.

About this study

Multi-center randomized study comparing dynamic assessment of fluid responsiveness utilizing Starling SV monitor compared to a control group.

Subjects will be randomized in a 2:1 treatment to control group ratio to increase power for sub-analysis by patient population.

Patients randomized to the Starling SV arm will have treatment guided by a dynamic assessment of fluid responsiveness (measured by a change in stroke volume index > 10%) as assessed by passive leg raise (PLR).

Patients randomized to the control group will receive standard of care treatment.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Diagnosis of sepsis, as exhibited by 2 or more of the following systemic inflammatory response syndrome (SIRS) criteria and a known or presumed infection at time of screening:
  • Temperature of > 38 C or < 36 C
  • Heart rate of > 90/min
  • Respiratory rate of > 20/min or PaCO2 < 32 mm Hg (4.3 kPA)
  • White blood cell count > 12000/mm3 or < 4000/mm3 or >10% immature bands
  • Refractory hypotension despite initial fluid resuscitation (1L of treatment fluid)
  • Patient enrolled in study as soon as possible (ideal window of 0-12 hours) and within 24 hours of arrival to the hospital
  • Anticipated ICU admission
  • Able to provide signed informed consent or consent can be obtained from the patient's authorized representative

Exclusion criteria

  • Primary diagnosis of: acute cerebral vascular event, acute coronary syndrome, acute pulmonary edema, status asthmaticus, major cardiac arrhythmia, drug overdose, or injury from burn or trauma
  • Known aortic insufficiency, or aortic abnormalities
  • Hemodynamic instability due to active gastrointestinal hemorrhage
  • Patient has received >3 liters of IV fluid prior to study randomization
  • Requires immediate surgery
  • Patient transferred to the ICU from another hospital unit
  • Do not attempt resuscitation (DNAR or DNR) order
  • Advanced directives restricting implementation of the resuscitation protocol
  • Contraindication to blood transfusion
  • Attending clinician deems aggressive resuscitation unsuitable
  • Transferred from another in-hospital setting
  • Not able to commence treatment protocol within 1 hour after randomization
  • Known intraventricular heart defect, such as ventral septal defect or atrial septal defect
  • Use of additional hemodynamic monitoring involving stroke volume variation (SVV) to determine fluid responsiveness
  • Seizure in the last 24 hours
  • Prisoner
  • Pregnancy
  • Age <18
  • Known allergy to sensor material or gel
  • Inability or contraindication to doing a passive leg raise with both extremities, such as inability to interrupt venous compression boots
  • Patient has an epidural catheter in place
  • Suspected intra-abdominal hypertension
  • Inability to obtain IV access
  • Diabetic ketoacidosis
  • Hyper-osmolarity syndrome
  • Patient uncouples from treatment algorithm
  • Patient should be excluded based on the opinion of the Clinician/Investigator

Treatment and study plan

Treatment Starling SV monitor

Device

A dynamic assessment of fluid responsiveness will be performed at every clinical decision point for the first 72 hours of study enrollment. Fluid responsiveness will be assessed using a passive leg raise (PLR) and Starling SV hemodynamic monitor to guide corresponding treatment.

Primary outcomes

  1. Fluid Balance

    Time frame: 72 hours

    Fluid balance is defined as all intravenous fluids administered over a 72 hour period (or ICU discharge, whichever occurred first), minus all fluid output. Urine output was measured in the ICU in 12 hour increments.

Secondary outcomes

  1. Percentage of Participants Requiring Renal Replacement Therapy

    Time frame: Day 1 to Day 30

    Renal replacement therapy (RRT) is therapy that replaces the normal blood-filtering function of the kidneys. It is used when the kidneys are not working well, which is called kidney failure and includes acute kidney injury and chronic kidney disease. Patient receives new treatment with dialysis.

  2. Percentage of Participants Requiring Ventilator Use

    Time frame: Day 1 to Day 30

    Patients did not enter the study on ventilation, but required ventilator use during the study are included in the analysis.

  3. Length of ICU Stay

    Time frame: Day 1 to Day 30

    Intensive Car Unit (ICU) length of stay will be calculated using the earliest of date that the subject is medically ready for discharge when captured, the date of discharge, or the study exit date.

  4. Number of Hours of Ventilator Use

    Time frame: Day 1 to Day 30

    Patients that did not enter the study on ventilation, but required ventilator use during the study are included in the analysis.Ventilator use might have improved (less use of ventilator support), had no change, or worsened (more use of ventilator support).

  5. Number of Hours of Vasopressor Use

    Time frame: Day 1 to Day 30

    Vasopressor drugs are provided to restore and maintain blood pressure in patients with septic shock. Patients that have vasopressors initiated throughout the trial are included in this analysis.

  6. Change From Baseline in Serum Creatinine Levels at 72 Hours

    Time frame: Baseline, 72 hours

    The diagnosis of Acute Kidney Injury (AKI) is traditionally based on a rise in serum creatinine

Other outcomes

  1. Volume of Fluid

    Time frame: 72 hours

    Traditional methods of assessing fluid responsiveness (FR) such as vital signs, physical examination, and static measurements of circulatory pressure have shown not to reliably correlate with fluid responsiveness. In contrast, dynamic measurement of stroke volume (SV) following an intravenous (IV) fluid bolus or passive leg raise (PLR) is a safe and feasible method of rapidly assessing the effectiveness of fluid-induced augmentation of SV and cardiac output (CO). Mean volume of treatment fluid Administered (ml) at 72 hours or ICU discharge, whichever occurs first, between the two treatment groups

  2. Percentage of Participants With Major Adverse Cardiac Event (MACE)

    Time frame: Day 1 to Day 30

    Incidence of cardiovascular death, nonfatal myocardial infarction, and nonfatal stroke.

  3. Number of Participants Experiencing an Adverse Event (AE) Related to Study Device

    Time frame: Day 1 to Day 30

    Adverse events associated with the treatment procedure.

  4. Percentage of Participants With Hospital Discharge Without ICU Readmission

    Time frame: Day 1 to Day 30

  5. Percentage of Participants Within Overall 30 Day Mortality Rate

    Time frame: Day 1 to Day 30

    Incidence of death.

  6. Number of Participants by Hospital Discharge Location

    Time frame: Day 1 to Day 30

    Patient location (either "home" or "other") following hospital discharge.

Sponsors and collaborators

Lead sponsor

Cheetah Medical Inc.

Industry

Registry information

Official study title

Evaluation of Fluid Volume in Patients With Sepsis and Refractory Hypotension

Acronym: FRESH

Important dates

Study start
2016
Primary completion
2019
Study completion
2019
First posted
Jul 20, 2016
Registry last updated
Dec 3, 2020

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.